Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Slides:

Advertisements

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Advertisements

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 2. Pharmacologic inhibition of ALK impairs STING activation.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

β-ARs signal cooperatively with mutant EGFR and inactivate LKB1

Fig. 1. Anemia in patients with central diabetes insipidus.

Fig. 3. Obese IFN-γ−/− mice develop accelerated NAFLD with fibrosis.

Fig. 4. Functional annotation of VUS in EGFR.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 4. Prion infectivity of skin samples from sCJD patients.

Fig. 1. NASH and fibrosis develop late in mice fed an HFD.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 4. Characterization of human liver seed graft morphology.

Intravenous delivery of reovirus to primary and secondary brain tumors

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 5. Vascularization of human liver seed grafts.

Dot plots of trisomic versus fetal fractions for cohorts 1 and 2

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 5 Acute loss of mitochondrial content after impact is prevented by inhibition of electron transport or critical redox events. Acute loss of mitochondrial.

Expression of THBS2 in human PanIN tissue and PDAC tumor tissue

Fig. 1. Generation of the ΔEx50 mouse model.

Fig. 4. MATE1 transcription in RCC.

Fig. 2 In vitro assessment of hESC-RPE cell sheets.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 1. Muscles of LAMA2 MD patients and dyW/dyW mice contain high amounts of laminin-α4 and show deficits in BM. Muscles of LAMA2 MD patients and dyW/dyW.

Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic.

Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder.

Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 3. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and CREB. β-AR signaling induces IL-6 in NSCLC cells via activation of PKC and.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 2 Analysis of CLL lymph nodes.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Acute lung injury in miR-223−/y mice.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Analysis of the bacterial nidus within tissue abscesses by MALDI IMS demonstrates a paucity of calprotectin signal. Analysis of the bacterial nidus.

Fig. 4 Spinally grafted iPSC-NPCs show long-term survival and neuronal and glial differentiation in syngeneic recipient in the absence of immunosuppression.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 1 Neutrophils derived from patients with MPNs are associated with an increase in NET formation and a prothrombotic, NET-rich phenotype. Neutrophils.

Fig. 5 Wireless, full-body pressure mapping on a human subject in a hospital bed. Wireless, full-body pressure mapping on a human subject in a hospital.

Fig. 1. Generation of the ΔEx50 mouse model.

Fig. 1 ZIKV RNA in blood and tissues.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

SIRT1 is downregulated in human gastric cancer (GC).

A 60-year-old man with HPV+ HNSCC (T3N2M0).

Fig. 1 Molecular imaging of EGFR-activating mutation status for stratification of patients. Molecular imaging of EGFR-activating mutation status for stratification.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 1. DEL-1 is expressed by human and mouse osteoclasts.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Representative CT and PET/CT images of three patients with NSCLCs

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.

Presentation transcript:

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. (A) Histological and amplification refractory mutation system (ARMS) polymerase chain reaction (PCR) confirmation of a patient (number 3) with EGFR exon 19 deletion: hematoxylin and eosin (H&E) staining at ×10 magnification. Scale bar, 100 μm. Immunohistochemistry for total-EGFR, phosphorylated EGFR (phospho-EGFR), and E746-A750del–specific EGFR at ×20 magnification from inset in (B). Scale bars, 50 μm. ARMS PCR: ΔCt = 18.57 < 26 (cutoff). (B) Histological and ARMS PCR confirmation of a patient (number 36) with EGFR exon 21 L858R point mutation: H&E staining at ×10 magnification. Scale bar, 100 μm. Immunohistochemistry for total-EGFR, phospho-EGFR, and L858R-specific EGFR at ×20 magnification from inset in (B). Scale bars, 50 μm. ARMS PCR: ΔCt = 21.83 < 26 (cutoff). (C) Histological and ARMS PCR confirmation of a patient (number 54) with wild-type EGFR: H&E staining at ×10 magnification. Scale bar, 100 μm. Immunohistochemistry for total-EGFR, phospho-EGFR, and E746-A750 del–specific EGFR at ×20 magnification from inset in (C). Scale bars, 50 μm. ARMS PCR: ΔCt = 113 > 26 (cutoff). Xilin Sun et al., Sci Transl Med 2018;10:eaan8840 Published by AAAS